In February 2015, the CDK4/6 inhibitor, palbociclib, in combination with letrozole, was approved by the FDA as first-line treatment of metastatic postmenopausal, hormone receptor (HR)-positive breast cancer. This evidence concerns the gene CDK4 and breast cancer.